Agreement - January 20, 2021
Recipharm signs manufacturing agreement with Enzymatica
Recipharm and Enzymatica have signed a broadened contract for the manufacture of ColdZyme. The agreement will involve an additional Recipharm production site in Pianezza, Italy, to support Enzymatica in increasing production volumes of ColdZyme to meet growing global demand. Both the facilities in Parets, Spain, and Pianezza, Italy, will be making additional investments to accommodate […]
Agreement - January 4, 2021
Iconovo signs agreement with Monash University
Iconovo has signed a development agreement with Monash University for the development of inhaled oxytocin in ICOone for maternal health. The agreement verifies the suitability of ICOone for use with innovative pharmaceuticals. Monash University’s Institute of Pharmaceutical Sciences (MIPS) is leading the development project supported by a research agreement with Janssen Pharmaceutica N.V., part of […]
Agreement - December 21, 2020
Nanoform and Herantis sign a letter of intent to collaborate
Nanoform Finland and Herantis Pharma have signed a letter of intent to collaborate to seek to enhance nasal drug delivery to the brain of Herantis’ CDNF and xCDNF therapies (Parkinson’s disease) using Nanoform’s biological nanoparticle technology. The planned and non-exclusive collaboration is intended to assess the utility of Nanoform’s latest platform technology for biologic drugs. […]
Agreement - December 18, 2020
Nanexa in investment agreement of USD 3 million
Nanexa has entered into an investment agreement with Applied Ventures, the venture capital arm of Applied Materials, whereby Applied Ventures intends to invest up to USD 3 million in Nanexa during 2021 to support continued development and expansion. USD 1 million will be invested in January 2021 and additional investments of up to USD 2 […]
Agreement - December 11, 2020
BioInvent and Cantargia sign manufacturing agreement
Cantargia and BioInvent International have announced that BioInvent has been contracted as manufacturer of Cantargia’s antibody CAN10 in preclinical development for the treatment of systemic sclerosis and myocarditis. CAN10 is fully humanized monoclonal antibody targeting IL1RAP. CAN10 has been designed to block the signalling of the inflammatory cytokines IL-1, IL-33 and IL-36 resulting in unique […]
Agreement - December 10, 2020
Orexo enters license and supply agreement with Accord Healthcare
Orexo has entered into an exclusive licensing agreement with Accord Healthcare, for the commercialization of ZUBSOLV ((buprenorphine (as hydrochloride) and naloxone (as hydrochloride dihydrate)) sublingual tablet. Licensed in Europe, ZUBSOLV is indicated for adults and adolescents over 15 years of age for substitution treatment for opioid drug dependence, within a framework of medical, social and […]
